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ABSTRACT
Although there are many reports on the regulation of ion 
channel expression in transcription and translation, few 
drugs have been studied to influence post-translational 
modification of ion channel proteins. The Kv1.5 channel 
is a potassium ion channel expressed in atrial muscle, 
belongs to the voltage-gated K+ channel superfamily, 
and forms an ultrarapid delayed rectifier potassium ion 
current. It is important to understand the fate of these 
channel proteins, as cardiac Kv1.5 mutations can cause 
arrhythmias. Disruption of quantitative and qualitative 
control mechanisms of channels leads to stagnation 
and degradation of intracellular channel proteins. As a 
result, ion channel proteins are not transported to the 
cell membrane and are involved in the development of 
atrial fibrillation. This review takes the Kv1.5 channel as 
an example and focuses on the degradation mechanism 
of ion channel proteins, and discusses its application to 
the treatment of arrhythmia by drugs that control the 
mechanism of ion channel protein degradation.
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Ion channels are membrane proteins responsible for 
the formation of resting membrane potential and action 
potential of the myocardium. The mRNA transcribed 
from the nuclear DNA is spliced when passing through 
the nuclear pore and translocating to the cytoplasm, 
and then an ion channel protein is formed on the ribo-
some as a protein having a primary structure. The ion 
channel protein having a primary structure undergoes 
post-translational modification such as folding and 
sugar chain modification via the endoplasmic reticu-
lum and Golgi apparatus, and is then transported to 
the cell membrane via microtubules. In addition, the 
transported ion channel proteins function by binding to 
anchor proteins present on the membrane.1, 2 To date, 
there have been many reports on the regulation of ion 
channel expression in transcription and translation, 
but few studies on drugs that affect post-translational 
modification of ion channel proteins. The Kv1.5 channel 
is a potassium ion channel expressed in atrial muscle, 
belongs to the voltage-gated K+ channel superfamily and 
forms ultrarapid delayed rectifier K+ currents (IKur) in 
the myocardium.3 Since mutations in the cardiac Kv1.5 
can cause arrhythmias,4 it is important from a cell biol-
ogy perspective to understand the fate of these channel 
proteins. Disruption of the quantitative and qualitative 
control mechanisms of the channel due to innate and 
acquired factors leads to stagnation and degradation of 
the channel protein in the cell. As a result, ion channel 
proteins are not transported to the cell membrane and 
are involved in the development of atrial fibrillation.5 
This review takes the Kv1.5 channel as an example and 
focuses on the degradation mechanism of ion channel 
proteins, and describes its application to the treatment 
of arrhythmias by drugs that control the mechanism of 
ion channel protein degradation.
MOLECULAR MECHANISM THAT REGULATES 
THE DEGRADATION RATE OF ION CHANNEL 
PROTEINS
As previously mentioned, the quantity and quality of 
proteins is determined by transcription and translational 
synthesis, and degradation by lysosomes and protea-
somes. In the process of post-translational modification 
of cell membrane proteins, proteins translated by 
cytoplasmic ribosomes are first transported to the 
endoplasmic reticulum based on mRNA transcribed in 
the nucleus. After cleavage of the signal sequence and 
transfer of the core sugar chain, they undergo quality 
control by molecular chaperones, followed by complete 
sugar chain modification, and are transported to the cell 
membrane via the Golgi apparatus (Fig. 1).1, 2
The channel protein functions after being trans-
ported to the cell membrane following post-translational 
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modification, bound to the anchor protein existing in the 
cell membrane, and localized in the cell membrane. In 
these processes, if the protein undergoes complete fold-
ing and sugar chain modification, the protein becomes 
stable, escapes from the protein degradation system 
described below and reaches the cell membrane, and the 
amount of ion channel protein increases. On the other 
hand, some of the proteins recognized as incomplete in 
the endoplasmic reticulum are retrogradely transported 
from the endoplasmic reticulum to the cytoplasm, 
ubiquitinated, and then degraded by the proteasome 
(ubiquitin-proteasome system, UPS). In addition, some 
defective proteins are transferred from the Golgi or cell 
membrane to the lysosomal/endosome system and de-
graded. When these degradative systems are activated, 
the ion channel protein cannot reach the cell membrane 
and the ion channel activity is reduced. Target proteins 
that are degraded by UPS are ubiquitin-activating E1 
enzyme, ubiquitin-conjugating E2 enzyme, and ubiq-
uitin E3 ligase, which are ubiquitin molecules that are 
covalently linked to their lysine residues. The ubiquiti-
nated proteins are degraded by the threonine protease 
26S proteasome.6, 7 Increased expression of channel 
proteins at cell membranes due to slower protein deg-
radation is referred to as protein stabilization, and as 
a result of protein stabilization, expression of channel 
proteins at cell membranes is increased (Fig. 1).
The degradation of channel proteins is defined by 
(1) degradation by proteasome, (2) ubiquitination in cy-
toplasm, and (3) folding and sugar chain modification in 
endoplasmic reticulum (Fig. 1). Therefore, degradation 
of Kv1.5 channel proteins is delayed by the proteasome 
inhibitor, and as a result, expression of Kv1.5 channel 
proteins on the membrane is stabilized (Fig. 1). The deg-
radation of channel proteins and stabilization of channel 
protein expression in the membrane could be achieved 
Fig. 1. Overall view of the anterograde trafficking of the normal Kv1.5 proteins. The degradation of channel proteins is defined by (1) 
ubiquitination, (2) degradation by proteasome in cytoplasm, and (3) folding and sugar chain modification in endoplasmic reticulum. 
The degradation of channel proteins and stabilization of channel protein expression in the membrane could be achieved by one of the 
following methods: promotion of protein folding and glycosylation at endoplasmic reticulum level; control of protein ubiquitination at 
cytoplasmic level; inhibition of protein degradation in the proteasome at cytoplasmic level.
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by one of the following methods: promotion of protein 
folding and glycosylation (control at endoplasmic reticu-
lum level); control of protein ubiquitination (control at 
cytoplasmic level); inhibition of protein degradation in 
the proteasome (control of final degradation apparatus).
INHIBITION OF PROTEASOME AND STABILI-
ZATION OF KV1.5 CHANNEL
Kv1.5 channels are degraded by UPS and classified into 
proteins with short half-lives. Our in vitro studies using 
cultured cells and forced expression of the Kv1.5 chan-
nel gene showed a half-life of Kv1.5 channel protein of 9.2 
hours.8 Pretreatment of MG132, a proteasome inhibitor, 
extended the half-life of Kv1.5 channel. Furthermore, 
the expression of Kv1.5 channel proteins was stabilized 
at the membrane with an increase in ubiquitination after 
treatment with MG132.
Then, inhibition of proteasome increases the ex-
pression of Kv1.5 channel protein, but how does it affect 
the intracellular trafficking of Kv1.5? To clarify this, 
we investigated the intracellular localization of Kv1.5. 
As a result, the localization of Kv1.5 channel proteins 
was consistent with the distribution of endoplasmic 
reticulum (reticulated distribution in the cytoplasm) 
and Golgi apparatus (distribution around the nucleus).8 
We observed that proteasome inhibition increased the 
localization of Kv1.5 channel proteins in both the endo-
plasmic reticulum and the Golgi apparatus.8
In electrophysiological studies, proteasome inhibi-
tion significantly increased 4-AP (4-aminopyridine) 
-sensitive IKur (ultrarapid delayed rectifier K+ current) 
compared to controls. This increase in IKur due to 
proteasome inhibition was abolished by brefeldine 
A, a selective inhibitor of endoplasmic reticulum-to-
Golgi protein transport, and colchicine, a microtubule-
blocking drug.8 From the above, it was shown that when 
the proteasome system was suppressed, the Kv1.5 chan-
nel protein increased its expression at the cell membrane 
through the endoplasmic reticulum-Golgi apparatus, 
and thereby its channel activity increased (Fig. 1).
KV1.5 CHANNEL PROTEIN STABILIZATION 
VIA PROTEASOME INHIBITION BY NA+ CHAN-
NEL INHIBITORS
Proteasome is a huge protein with a molecular weight 
of 26S consisting of 19S of regulatory subunit and 20S 
subunit having an active center. The 20S proteasome of 
eukaryotic cells has three types of protease activities: 
caspase-like activity (cleaving acidic amino acids), 
trypsin-like activity (cleaving basic amino acids), and 
chymotrypsin-like activity (cleaving hydrophobic or 
aromatic amino acids).9 These three types of activities 
are localized in β1, β2, and β5 subunits, respectively. 
The mammalian β5 subunit shares 67% homology with 
yeast and has chymotrypsin-like activity.10 Structural 
biology has shown that classical proteasome inhibitors 
such as MG132 inhibit their activity by covalently 
binding to the chymotrypsin-like active site of the 20S 
proteasome β subunit.10
Recently, we reported that aprindine, a Na+ channel 
inhibitor belonging to class 1b, stabilizes Kir6.2 proteins 
that are degraded in proteasome, and its mechanism of 
action may be the inhibitory effect of 20S proteasome
Since Na+ channel blockers such as pilsicainide and 
lidocaine have an aromatic ring and an amide bond, and 
this structure is similar to that of proteasome inhibi-
tors, it was hypothesized that these drugs may have an 
inhibitory effect on the proteasome. According to our 
hypothesis, the administration of pilsicainide markedly 
extended the half-life of Kv1.5 channel proteins and 
significantly increased its expression.8 Administration 
of pilsicainide significantly increased ubiquitination of 
Kv1.5, and markedly increased intracellular localization 
of Kv1.5 channel proteins in Golgi and endoplasmic 
reticulum. Furthermore, administration of pilsicainide 
significantly increased IKur current in COS7 cells 
expressing Kv1.5 genes. Next, the effect of ion channel 
inhibitors on 20S proteasome activity was measured.8 
As a result, the Na+ channel inhibitors pilsicainide and 
lidocaine dose-dependently suppressed 20S proteasome 
activity, and their IC50 were 1.2 μM and 75 μM, respec-
tively; on the other hand, K+ channel inhibitors and Ca2+ 
channel antagonists did not suppress their activity.
Next, we hypothesized that the difference in IC50 
between pilsicainide and lidocaine was due to the 
difference in proteasome inhibitory action mode. The 
structure of bovine 20S proteasome is known at the 
crystallographic level. Therefore, for the purpose of ver-
ifying this hypothesis, we examined the binding mode 
of pilsicainide and lidocaine to the active site of bovine 
proteasome using the docking test.11–13 Interestingly, it 
was revealed that the binding sites of pilsicainide and 
lidocaine are different from the nucleophilic reaction 
site of β5 subunit, Thr1, (Fig. 2). That is, in general, 
a binding site of proteasome inhibitor is an S1 site 
containing Thr1 which is a nucleophilic reaction site of 
β5 subunit.11–13 However, in the results of model experi-
ments, the binding site of pilsicainide and lidocaine was 
an S1’ site near the S1 site, but not the S1 site.14 It was 
suggested that both drugs stably occupy the S1’ site by 
binding to the S1’ site and further by hydrogen-bonding 
the amide groups of pilsicainide and lidocaine between 
Gly129 and Tyr113 of the proteasome.14 Since this S1’ 
site is the binding site of the target protein that is cleaved 
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by the chymotrypsin-like activity, it was thought that 
inhibition of this binding site would suppress the degra-
dation of the protein and stabilize the expression. From 
the structure of this S1’ site, it was considered possible 
to explain the difference in the strength of the protea-
some inhibitory action of pilsicainide and lidocaine 
(Fig. 2). That is, in pilsicainide, its pyrrolidine ring can 
sufficiently fit in the recess before the S1’ site, while li-
docaine does not have a pyrrolidine group so that the fit 
in the recess in the S1’ site is insufficient (Fig. 2). Based 
on this difference, the potency of proteasome inhibi-
tion of both drugs was considered to be different. This 
inhibition of proteasome activity and the stabilizing 
effect of Kv1.5 channel proteins were also confirmed by 
other Na+ channel inhibitors mexiletine and flecainide 
(unpublished data). The inhibitory effect of Na+ channel 
inhibitors on proteasome was considered to be a class 
effect (Fig. 2). Moreover, since it was suggested that the 
S1’ site could be a target site for the development of pro-
teasome inhibitors, future research in the development 
of new proteasome inhibitors is expected.
STABILIZATION OF KV1.5 CHANNEL PROTEIN 
BY MOLECULAR CHAPERONE
We searched for a protein that binds to Kv1.5 and found 
that one of the heat shock proteins (HSP), HSP70, binds 
to Kv1.5. The cytoplasmic molecular chaperones HSP70, 
HSC70 (heat shock cognate 70), and HSP90 play 
important roles in protein folding and degradation of 
proteins with abnormal folding.15, 16 In fact, overexpres-
sion of the HSP70 gene significantly increased the half-
life of Kv1.5 channel proteins degradation and increased 
protein expression at the cell membrane without altering 
the level of ubiquitinated Kv1.5 channel proteins.17 The 
results of co-immunoprecipitation experiments showed 
that Kv1.5 interacts with HSP70. Furthermore, the re-
sults of immunostaining experiments on cells revealed 
that Kv1.5 and HSP70 colocalized with the endoplasmic 
reticulum and the Golgi apparatus. And, overexpres-
sion of HSP70 gene markedly enhanced Kv1.5 channel 
proteins expression in the endoplasmic reticulum, 
Golgi apparatus and cell membrane from the results of 
immunostaining experiments, and the results of patch-
clamp experiments revealed that Kv1.5 currents were 
significantly increased in the test pulse range of +20 mV 
to +80 mV. The increase in Kv1.5 currents by HSP70 
Fig. 2. Molecular mechanism of proteasome inhibition by Na+ channel inhibitors and Kv1.5 protein stabilization. Pilsicainide occupies 
the peptide binding site and exerts a proteasome inhibitory effect, which is different from the chymotrypsin site where MG132 acts. 10 
μM lidocaine and 10 μM pilsicainide inhibited proteasome activity by 20% and 50%, respectively. Pilsicainide suppresses proteasome 
activity below clinical use levels by occupying the S1’ pocket of the proteasome (Kd = 1.99 mM).
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was abolished by brefeldin A and colchicine which are 
protein transport inhibitors. In addition, from the cell 
fraction extraction experiment, the expression level of 
Kv1.5 channel proteins in the endoplasmic reticulum 
fraction was increased by forced expression of the 
HSP70 gene. In summary, it was concluded that the 
molecular chaperone HSP70 acts on the endoplasmic 
reticulum to stabilize the structure of the Kv1.5 channel 
proteins (Fig. 3).17
STABILAIZION OF KV1.5 CHANNEL PROTEIN 
BY CONTROLLING UBIQUTIN LIGASE
Kv1.5 channel proteins are ubiquitinated and degraded 
by endoplasmic reticulum-related UPS, but the specific 
E3 ligase that ubiquitinates Kv1.5 channel proteins is 
unknown at present. The carboxyl-terminus of HSC70 
interacting protein (CHIP) was found as a co-chaperone 
that inhibits folding by HSP70, but was later shown to 
be an ubiquitin ligase dependent on cytoplasmic chaper-
one. CHIP has three N-terminal tetratricopeptide repeat 
(TPR) domains, which bind to the C-terminus of HSP70 
or HSP90, and a Ubox domain required for interaction 
with ubiquitin-conjugating E2 enzyme.18, 19 Therefore, 
we examined the possibility that CHIP acts as an E3 
ligase of Kv1.5.18, 19 When the wild-type CHIP gene was 
introduced, the degradation of Kv1.5 was promoted in a 
CHIP expression-dependent manner. On the other hand, 
the amount of Kv1.5 did not change when the Ubox 
domain of CHIP, which is the binding site of ubiquitin 
conjugating E2 enzyme, or the TPR domain, which 
is the binding site of CHIP to HSP70, was deleted. 
Furthermore, to confirm that CHIP regulates the degra-
dation of Kv1.5 channel proteins, we created inhibitory 
small interfering RNA (siRNA) against CHIP and 
introduced this into cells to suppress the endogenous 
CHIP in COS7 cells. As a result, Kv1.5 channel proteins 
increased depending on the decrease of CHIP expres-
sion. These results indicated that CHIP acts as an E3 
ligase for UPS degradation of Kv1.5 channel proteins. 
Taken together, it was considered that the binding of 
Fig. 3. The anterograde trafficking of the normal Kv1.5 proteins, and the degradation of misfolded Kv1.5 channel proteins dependent on 
an E3 ligase, CHIP. Left: Normal Kv1.5 proteins traffic to the membrane. Right: the misfolded Kv1.5 channel proteins undergo degrada-
tion by proteasome after poly-ubiquitination by an E3 ligase (CHIP) and an E2 ligase. Mutant CHIP proteins (E2 binding site defect, 
CHIPΔUbox or HSP70 binding site defect, CHIPΔTPR) fail to poly-ubiquitination of the Kv1.5 channel proteins. Novel treatments for 
arrhythmias suggested in the text are depicted.
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Kv1.5 and HSP70 stabilized the protein structure, CHIP 
could not ubiquitinate Kv1.5 channel proteins, and Kv1.5 
channel proteins expression was increased (Fig. 3).
STABILIZATION OF KV1.5 CHANNEL PRO-
TEINS BY A CHEMICAL CHAPERONE IN THE 
ENDOPLASMIC RETICULUM
It has been suggested that chronic administration of 
eicosapentaenoic acid (EPA), an n-3 polyunsaturated 
fatty acid, may influence the biosynthesis and intracel-
lular transport of Kv1.5 channels.20 We hypothesized 
that the antiarrhythmic effects of EPA are explained 
by modifications of myocardial ion channels. To prove 
the hypothesis, the effects of n-3 polyunsaturated fatty 
acids EPA and docosahexaenoic acid on Kv1.5 channel 
protein and channel activity were examined.20 As a 
result, chronic administration of EPA dose-dependently 
increased Kv1.5 channel proteins in the range of 0.1 to 
10 μM. From the study of intracellular distribution of 
Kv1.5 channel proteins, Kv1.5 channel proteins expres-
sion was markedly increased in endoplasmic reticulum, 
Golgi apparatus and cell membrane under chronic 
administration of 1 μM EPA. Consistent with this result, 
the Kv1.5 channel current IKur was also significantly 
increased. Examination of the mechanism of Kv1.5 
channel increasing action by this low concentration 
EPA revealed that EPA significantly extended the half-
life of Kv1.5 channel proteins. In addition, pretreatment 
with protein transport inhibitors abolished the effect of 
EPA on increasing Kv1.5 currents, suggesting that EPA 
acts mainly on Kv1.5 channel proteins localized on the 
endoplasmic reticulum membrane. Interestingly, acute 
treatment with 1 mM 4-AP increased Kv1.5 channel 
proteins, whereas 12-hour treatment with 4-AP abol-
ished the EPA-induced increase in Kv1.5 proteins. These 
facts suggest that EPA acts as a chemical chaperone by 
altering the structure of Kv1.5 channel proteins in the 
endoplasmic reticulum and stabilizing it by acting on 
the 4-AP binding site of Kv1.5 channel proteins (Fig. 3).
STABILAIZAION OF KV1.5 CHANNELS PRO-
TEINS BY ION CHANNERL ANCHOR PTOTEIN
Propagation of electrical excitation in myocardial tissue 
requires the formation of action potentials of cardio-
myocytes, and expression of voltage-gated K+ channels 
in the cell membrane is important for the formation of 
action potentials. The anchor protein containing the 
PSD95/Dlg/ZO-1 (PDZ) domain plays an important 
role in the organization and intracellular localization of 
voltage-gated K+ channels in the plasma membrane.21–24 
Synapse-associated protein 97 (SAP97) is an anchor 
protein that belongs to the membrane-associated 
guanylate kinase protein family that has a PDZ domain, 
and is an anchor protein that colocalizes with Kv1.5 at 
the intercalated disc of atrial and ventricular muscles 
(Fig. 1).25, 26 SAP97 stabilizes the Kv1.5 channel pro-
teins by binding via the amino acid on the carboxyl-
terminal side of the Kv1.5 channel proteins. From the 
results of immunostaining and immunoprecipitation 
experiments using mouse atrial myocytes, HL-1 cells, 
it was confirmed that SAP97 and Kv1.5 co-localize.26 
Furthermore, it was observed that overexpression of 
the SAP97 gene increased the expression level of Kv1.5 
channel proteins. From these results, it was speculated 
that the Kv1.5 channel proteins and the anchor protein 
SAP97 were post-translationally modified and stabilized 
on the endoplasmic reticulum and that SAP97 and Kv1.5 
interact with each other to stabilize the proteins (Fig. 1). 
Recently, we revealed that geranylgeranylacetone (GGA) 
that induces heat shock factor (HSF) -1 and HSP70 di-
rectly stabilize the Kv1.5 channel proteins by increasing 
the transcriptional activity of SAP97.26 From the results 
of the reporter assay, it was confirmed that the HSF-
1 binding domain was present in the transcriptional 
regulatory region of the SAP97 gene. From the above, it 
is considered that regulation of SAP97 protein expres-
sion by heat shock proteins may be applicable as a novel 
arrhythmia treatment via a mechanism that regulates 
expression in an intervening version of Kv1.5 channel 
proteins (Fig. 3).25–27
CONCLUSION
In this paper, I reviewed the possibilities of a novel treat-
ment for arrhythmias via the control of the degradation 
of ion channel proteins (Fig. 3). In order to stabilize the 
expression of ion channel proteins on the cell membrane 
and maintain channel activity by controlling protein 
degradation, several strategies such as those discussed 
in this review can be considered (Table 1): Proteasome 
inhibition (e.g., MG132 and Na+ channel inhibitor); 
Delayed degradation by suppressing ubiquitination (e.g., 
CHIP inhibition); Acceleration of protein folding and 
sugar chain modification in the endoplasmic reticulum 
(e.g., chemical or molecular chaperones such as EPA 
and SAP97). Further development of research in this 
field is expected in the future.
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